Bladder cancer refers to the malignant overgrowth of cells within the bladder. The most common site of overgrowth is the inner lining of the bladder (mucosal epithelium). These lining cells, known as urothelial cells, give rise to urothelial carcinoma—which accounts for 90%-95% of all bladder cancers and represents the most prevalent type.
Rising Incidence
Global Rank: Indonesia ranks 15th worldwide in incidence and 13th in mortality (2022 data).
New Cases: ~7,381 new cases and 3,207 deaths in 2022, with a mortality rate of 43.4%.
Growth Trend: Annual malignant disease growth in Indonesia reached 8% over the past decade. Bladder cancer, as a common urological tumor, grows significantly faster than in some Southeast Asian nations.
Gender and Age Distribution
Male Dominance: Incidence in men is >3× higher than in women, directly linked to high global male smoking rates (>65% in Indonesian males).
High-Risk Age: >70% of cases occur in people aged 50+, but delayed diagnosis in younger patients (e.g., age 32) rises annually.
| Treatment Dimension | Current Practice in Indonesia | Fosunhealth Hospitals Advantage |
|---|---|---|
| Surgical Technique | Primarily open surgery (highly invasive) | da Vinci robotic minimally invasive surgery: Less bleeding, faster recovery |
| Radiotherapy Equipment | Conventional radiotherapy (damages adjacent organs) | CyberKnife non-invasive precision: Spares healthy tissue |
| Targeted/Immunotherapy | Limited genetic testing; expensive self-paid drugs | Molecular diagnostics + Guangdong-Macao Drug/Device Access Program: Globally aligned protocols |
| Organ Preservation | Predominantly total cystectomy; poor stoma care | Orthotopic neobladder reconstruction: Near-physiological urination |
| Cost Accessibility | Narrow insurance coverage; 60% surgery refusal rate | Commercial insurance direct billing + reimbursement: Controllable costs |
